Roche Holding AG (RHHBY)
| Market Cap | 342.35B |
| Revenue (ttm) | 79.83B |
| Net Income (ttm) | 11.86B |
| Shares Out | n/a |
| EPS (ttm) | 14.77 |
| PE Ratio | 28.88 |
| Forward PE | 16.72 |
| Dividend | 0.87 (1.73%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 3,816,632 |
| Average Volume | 2,742,804 |
| Open | 50.02 |
| Previous Close | 50.43 |
| Day's Range | 49.43 - 50.30 |
| 52-Week Range | 34.10 - 50.67 |
| Beta | 0.17 |
| RSI | 65.45 |
| Earnings Date | Jan 29, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.
Financial numbers in CHF Financial StatementsNews
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
Roche Holding AG (RHHBY) Shareholder/Analyst Call - Slideshow
Roche's Oral Breast Cancer Drug Shows 30% Drop In Recurrence In Patients With Early Disease
On Wednesday, Roche Holdings AG (OTC: RHHBY) shared data from the phase 3 lidERA Breast Cancer study. The study evaluated giredestrant as an adjuvant endocrine treatment for oestrogen receptor (ER)-p...
Roche's Breast Cancer Drug Cuts Risk of Death by 30% in Phase III
RHHBY's giredestrant cuts the risk of invasive disease recurrence or death by 30% in phase III, fueling momentum for a next-generation endocrine therapy.
Roche Secures CE Mark Approval For Automated Mass Spectrometry Reagent Pack
(RTTNews) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has obtained CE Mark approval for its mass spectrometry reagent pack designed for antibiotics drug monitoring. This milestone establishes Roc...
Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry's broadest in vitro diagnostic menu
Basel, 11 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has secured CE Mark approval for its mass spectrometry reagent pack for antibiotics drug monitoring. This establish...
Questex's Patients as Partners® in Clinical Research Unveils Conference Program, Thought Leaders from Lurie Children's Hospital, Roche Canada and Tufts University School of Medicine to Keynote
Patients as Partners® in Clinical Research Now Part of Questex's Fierce Life Sciences Portfolio; First Conference to Put Patients at the Same Level as R&D Executives in a National Event Takes Place in...
Roche's SERD Trial Boosts Olema Pharmaceuticals (OLMA) Stock
Roche's SERD Trial Boosts Olema Pharmaceuticals (OLMA) Stock
Roche Says Breast-Cancer Drug Shows Potential to Become Standard-Of-Care
Giredestrant lowered the risk of disease recurrence or death by 30%, compared with standard-of-care endocrine therapy, according to the company.
Roche boosts Olema after additional late-stage trial data for breast cancer drug
Genentech's Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-positive Early-Stage Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive data from the Phase III lidERA Breast Cancer study evaluatin...
Roche breast cancer pill cuts risk of disease recurrence by 30% in trial
Roche said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer recurrence by 30% compared with standard endocrine therapy, in what it said marked the first big advan...
Roche's giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer
Basel, 10 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive data from the phase III lidERA Breast Cancer study evaluating investigational giredestrant as an adjuvant endocrin...
Roche Announces CE Mark For Its Cobas BV/CV Assay
(RTTNews) - Roche (RHHBY, RO.SW) announced the CE Mark for its cobas BV/CV assay to identify specific bacteria and yeast responsible for BV and CV in vaginal samples from symptomatic patients collecte...
Roche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark
Basel, 9 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the CE Mark for its cobas® BV/CV (Bacterial Vaginosis/Candida Vaginitis) assay to accurately identify specific bacteria and ...
European Commission approves Roche's Gazyva/Gazyvaro for adults with active lupus nephritis
Basel, 9 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Gazyva®/Gazyvaro® (obinutuzumab) in combination with mycophenolate mofetil (MMF) f...
Roche (RHHBY) Reports Promising Lunsumio Study Results
Roche (RHHBY) Reports Promising Lunsumio Study Results
Genentech Presents Lunsumio Data Showing Potential Across Earlier Treatment Lines in Indolent and Aggressive Lymphomas
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new data highlighting the potential of Lunsumio® (mosunetuzumab-axgb)...
Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas
Basel, 8 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new data highlighting the potential of Lunsumio® (mosunetuzumab) in earlier treatment lines for people living with different...
Roche May Be Riding A Bit Too High, But Remains Interesting
Roche stock could be interesting for patient investors. Learn more about its outlook, pipeline prospects, and upcoming catalysts.
Orano Med Enters Next Phase of Collaboration With Roche
CHÂTILLON, France--(BUSINESS WIRE)--Orano Med's collaboration with Roche to develop “two-step pretargeted radioimmunotherapy” (or PRIT) ready to advance into clinical development.
Wall Street Just Woke Up to Roche--Here's Why It Could Be Pharma's Next $10 Billion Breakout
Wall Street Just Woke Up to Roche--Here's Why It Could Be Pharma's Next $10 Billion Breakout
Roche (RHHBY) Shares Surge on Promising Drug Developments
Roche (RHHBY) Shares Surge on Promising Drug Developments
Roche shares hit milestone with 19% November surge on breast cancer and promising MS drug trials
Sure! Please provide the article or input text you'd like a meta description for.